Bal Pharma Limited Overview
Bal Pharma Limited is a Bengaluru-based micro-cap pharmaceutical manufacturer that has been in business for nearly four decades. It is vertically integrated across pharma intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs). Its strategic core is a niche API franchise. The anchor product is the anti-diabetic molecule Gliclazide: ICRA has stated that Bal Pharma held roughly a 25% global market share in Gliclazide and that the molecule generated about 45% of group revenue. The company exports APIs to regulated and semi-regulated markets in Europe, Japan, Australia, Canada, Latin America and Asia, serving customers such as Krka, Apotex, Mylan, Takeda, Novartis and Sun Pharma. Domestically, it sells branded prescription generics, intravenous fluids and Ayurvedic products through specialty divisions. It also runs an OTC subsidiary, Lifezen Healthcare. Annual revenue is about INR 310 crore (FY2026). The business is characterised by thin net margins (about 2%), high leverage (net debt about 4.7x EBITDA) and a promoter holding of 50.86%. It is now trying to scale through new API capacity and a Philippines distribution JV.
Company's own description
The company's website and annual report describe Bal Pharma as a leading Indian pharmaceutical company with more than 32 years of experience. Its stated specialisations are prescription drugs, generic medicines and OTC products, intravenous infusions and bulk actives. Its APIs are exported mainly to Europe, the Far East, Latin America, Africa and the Middle East. Its finished formulations go to semi-regulated and non-regulated markets, and the company says it is "foraying" into regulated markets. It also describes itself as a strong contender for international tender business. Exchange profiles and the annual report summary describe it as "a fully integrated pharmaceuticals company specialising in Bulk Drugs, Prescription Drugs, Generics, Pharma intermediates, and Ayurvedic products" (Screener / Annual Report).
Independent characterisation
Bal Pharma operates as a two-engine business:
-
API and intermediates (export-led, B2B). The company makes a concentrated basket of 22+ niche API molecules and intermediates, sold mainly to generic formulators abroad. Concentration is very high. In H1 FY2022 the top five APIs contributed about 94% of API revenue (company press release, Nov 2021). ICRA (Sept 2021) estimated that Gliclazide alone produced 60–65% of API revenue and around 45% of total revenue. The economics resemble a specialty API supplier: revenue depends on customers' finished-product registrations (DMF/CEP filings), regulatory approvals at the plant and the competitive intensity of each molecule.
-
Formulations (domestic branded generics plus export FDF). In India, the company runs prescription divisions focused on diabetes, cardiology and general therapy. Examples include the Glyduz division, which launched Sitagliptin as SITABEND and SITABEND-M in October 2022, and the older Servetus division (2001). The company has stated that it serves domestic customers through more than 1,000 wholesalers, about 100,000 retailers and about 600 field professionals covering roughly 100,000 doctors. Export formulations go mainly to semi-regulated markets and international tenders. The company also makes IV fluids at Pune and Ayurvedic/herbal products. Consumer OTC products are sold through Lifezen Healthcare (for example, the "Eye Spa" eye lubricant).
Revenue model
| Revenue stream | Model | Customer type | Disclosure status |
|---|---|---|---|
| API / intermediates exports | Product sales (B2B, supply agreements, DMF-linked) | Generic formulators, multinationals (Krka, Apotex, Mylan/Viatris, Takeda, Novartis, Actavis, Sun Pharma per investor presentation) | Share of revenue not disclosed for FY2026 |
| Domestic API | Product sales (B2B) | Indian formulators | — |
| Domestic branded formulations | Product sales via distributors and retailers; promoted by medical representatives | Doctors, chemists, hospitals | — |
| Export formulations | Product sales, tenders | Distributors and governments in semi-regulated markets; tender agencies | — |
| IV fluids | Product sales | Hospitals, institutions | — |
| Ayurvedic / OTC (incl. Lifezen) | Product sales (B2C via retail) | Consumers | — |
| Contract manufacturing | Toll / loan-licence manufacturing | Other pharma companies | Mentioned by third-party profiles (TipRanks); not quantified |
| Licensing / subscription | None identified | — | — |
Value-chain position and export/domestic mix
Bal Pharma's integration runs from intermediates (Sangli) → API (Bengaluru Unit 2, Udaipur Unit 6, new Karnataka capacity) → FDF (Bengaluru Unit 1, Rudrapur Unit 4, Pune Unit 3 for IV). This backward integration supports its cost position in Gliclazide and related molecules.
The export-to-domestic revenue mix was 64:36 in H1 FY2022 and 71:29 in Q1 FY2023 (company press releases). A FY2026 split is not publicly disclosed in the sources reviewed.
Strategy
Stated strategy
Management's long-standing stated strategy (Nov 2021 press release) is to "focus on API exports and Domestic formulations" over the medium to long term. In a PharmaBoardroom interview, MD Shailesh Siroya explained that Bal Pharma deliberately targeted niche rather than commodity APIs. He said this let the company build a global position while competing on quality, timely delivery and regulatory support rather than price. He also highlighted the post-COVID government push (PLI schemes) to reduce India's dependence on imported APIs. The company has stated that it is a PLI beneficiary.
Initiatives in the last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| Golden Drugs amalgamation | Effective 26 Mar 2025 | Simplifies structure and consolidates Udaipur API into the parent | Completed |
| Proposed Lifezen Healthcare merger | Considered Aug 2025; deferred Nov 2025 | Fold the OTC subsidiary into the parent | Deferred pending data |
| ESOP scheme | 2025–2026 board/AGM items | Employee retention | — |
| New API capacity (Yadgir / Gauribidanur) | Production from June 2026 per Acuité | Capacity expansion; partly debt-funded | Ramp-up |
| Promoter warrant issue | Approved 27 May 2026; allotted 2026 | 10 lakh warrants at INR 84 to Shailesh Siroya (INR 8.4 crore) | Allotted; conversion pending |
| Philippines JV | Approved 12 Aug 2026 | 65% Bal Pharma / 35% Hemera; Bal Pharma as manufacturer, Hemera as supply-chain partner | Incorporation pending/unconfirmed |
| Director designation changes | Effective 1 Oct 2026 | Board reorganisation | Effective |
| Regulated-market FDF push | Ongoing | EU-GMP formulation list; Gliclazide MR in the EU | Ongoing |
| Sustainability page | Ongoing | Website section exists; no targets found | — |
Medium-term targets and guidance
Not publicly disclosed. The company does not hold earnings calls or publish numeric guidance, and no investor-day targets were found. Univest notes that no verified analyst estimates exist for FY2027.
Products & Services
The company publishes downloadable API, API-intermediate and formulation product lists, including an EU-GMP formulation list, on its website. Those PDFs were not parsed in this research. The portfolio below is built from disclosed molecules and brands; molecule-level revenue is not publicly disclosed.
API and intermediates (B2B, mainly export)
| Product | Therapeutic use | Notes / target customer | Launch / status |
|---|---|---|---|
| Gliclazide | Anti-diabetic (sulfonylurea) | Flagship API. About 25% global share (ICRA 2021); supplied to regulated markets including Europe | Core since the API start (1996); EU Gliclazide MR 30/60 mg formulations planned (2021) |
| Ebastine | Antihistamine | Niche API for European and Asian formulators | Products rolled out around 2002; included in Gauribidanur 270 TPA plan |
| Amiloride HCl | Potassium-sparing diuretic | Niche cardiovascular API | Products around 2002 |
| Benzydamine HCl | NSAID (oral and topical analgesic, anti-inflammatory) | Niche API used in mouthwashes and sprays | Products around 2002 |
| Pregabalin | Neuropathic pain / anticonvulsant | Higher-volume API added to the new-capacity plan | Planned for the Gauribidanur unit (2016-17) |
| Other 17+ APIs and intermediates | Various | Company claims 22+ API/intermediate molecules | Not individually disclosed |
Capacity (company presentations, about 2021–22): Unit 2 Bangalore API 120 TPA, Unit 6 Udaipur API 180 TPA, total about 370 tonnes of API capacity. A further 270 TPA was planned at Gauribidanur, and Yadgir is under development. Acuité's rating rationale says production at the new facility was to commence from June 2026.
Domestic formulations (branded generics)
| Division / brand | Molecule(s) | Therapy | Year |
|---|---|---|---|
| Glyduz division – SITABEND | Sitagliptin | Diabetes (DPP-4 inhibitor) | Oct 2022 |
| Glyduz division – SITABEND-M | Sitagliptin + Metformin | Diabetes | Oct 2022 |
| Servetus division | Specialty products | Specialty | 2,001 |
| Cardiac specialities range | Various | Cardiology | Not dated |
| Gliclazide-based formulations | Gliclazide (IR/MR) | Diabetes | Not dated |
| General / ethical range | Paracetamol, aluminium hydroxide and others | Analgesics, antacids | Legacy |
Export formulations
The company exports FDFs (tablets, capsules and others) to semi-regulated and non-regulated markets and to international tenders. A separate EU-GMP formulation list indicates a regulated-market dossier pipeline. Unit 4 at Rudrapur is the main FDF export plant. Market-by-market product registrations are not publicly disclosed.
Intravenous infusions
Large-volume parenterals (IV fluids) are made at Unit 3, Pune, which has been operating since 1997. Product specifications are not publicly disclosed.
Ayurvedic and herbal
The company offers an Ayurvedic/herbal range that "integrates modern medicine with Ayurvedic/herbal preparation" and publishes a downloadable Ayurvedic brochure. Individual brands are not disclosed in the sources reviewed.
Consumer OTC (Lifezen Healthcare)
The flagship disclosed product is Eye Spa, an eye lubricant. Pricing is not disclosed.
Services
-
Contract and loan-licence manufacturing (not quantified).
-
Clinic and healthcare services through Balance Clinics LLP (scale not disclosed).
-
Research and analytical services through Bal Research Foundation and Aurum Research & Analytical Solutions (scale not disclosed).
Pricing model. Domestic branded generics are priced under India's DPCO/NPPA framework where scheduled. API prices are negotiated B2B. Specific prices are not disclosed.
Financial Narrative
Basis: consolidated financial statements as transcribed by stockanalysis.com (INR millions converted to INR crore by dividing by 10). EBITDA follows Screener's "operating profit". Figures are rounded to one decimal place. EPS for FY2025–FY2026 is as reported (fyers.in); earlier EPS figures are derived from net income and shares outstanding and are flagged.
Income statement
Notes: (a) FY2026 net profit attributable to the parent is reported as INR 6.28 crore by fyers.in and INR 6.32 crore by Tijori. Standalone FY2026 net profit was INR 6.75 crore (₹675.12 lakh, down 13.4%) on standalone revenue of ₹31,079.70 lakh (up 2.7%). (b) Total income including other income was INR 313.59 crore in FY2026 vs INR 305.29 crore in FY2025 (fyers.in). (c) FY2026 depreciation was INR 11.08 crore and finance costs INR 17.02 crore (fyers.in). Screener payout ratios (FY2022: 26%, FY2023: 61%, FY2024: 26%) imply roughly INR 1.0–1.2 per share, but this is not confirmed. A 12% dividend (INR 1.20) went ex-date on 18 September 2025 for FY2025, and INR 1.20 was recommended for FY2026.
Margin profile
Revenue CAGR: FY2022–FY2026 (4 years) about 2.6% (derived: (311.7/281.2)^(1/4) – 1). Over a longer horizon, Screener shows 5-year sales growth of 4.51% and 10-year growth of about 5%. Consolidated revenue was INR 179 crore in FY2014.
Commentary. The defining pattern is gross-margin expansion that does not reach the bottom line. Gross margin rose by about 10.5 percentage points between FY2022 and FY2026. That reflects a shift away from low-margin API volume, the fall in COGS after FY2024 as raw-material (KSM) prices eased, and a richer domestic formulations mix. However, SG&A and "other operating expenses" (power, freight, R&D and plant overheads) grew in step. As a result, EBIT margin improved only from 5.3% to 6.7%.
Interest is the binding constraint. Interest expense nearly doubled, from INR 8.9 crore (FY2022) to INR 16.8 crore (FY2026), as net debt rose. It now absorbs about 80% of EBIT. The FY2025 revenue decline (–10.7%) was the main inflection. The quarterly pattern shows sharply weaker Q1 FY2026 revenue (INR 65.9 crore), consistent with API destocking or pricing pressure. Recovery came in H2 FY2026 and accelerated in Q1 FY2027 (INR 88.6 crore, +34.5% YoY). Reported net income in FY2025–FY2026 was flattered by negative tax charges (deferred-tax credits), so pre-tax profitability is weaker than PAT suggests.
Quarterly trajectory (most recent five quarters)
Sources: Kotak Neo result pages (Q1, Q3, Q4 FY2026); Univest (Q2 FY2026 and Q1 FY2027). Q3 FY2026 revenue is approximated from reported total income of INR 88.02 crore. Univest also cites Q1 FY2027 revenue of INR 89.06 crore and PAT of INR 1.14 crore (total income basis), a minor discrepancy against 88.62/1.13. Voguestock reported Q4 FY2026 net profit of INR 3.70 crore (–34.05%) versus Kotak's INR 3.60 crore.
Balance sheet
Notes: (a) The short-term/long-term debt split is not cleanly disclosed in aggregator data. TipRanks' long-term-debt-to-capital ratio of 0.34 against total debt-to-capital of 0.67 implies that about half of debt is long-term term loans and half is working-capital borrowings (cash credit, packing credit). (b) In April 2025, Bal Pharma's "initial disclosure" under SEBI's large-corporate framework cited borrowings of INR 43.14 crore. That figure refers only to long-term borrowings as defined in that framework, which is why the company was not classified as a large corporate. (c) Total equity: Screener's consolidated book value of INR 48.6/share (FY2025 snapshot) × about 1.59 crore shares gives about INR 77 crore. Acuité's August 2026 rationale cites a net worth of about INR 65 crore at 31 March 2026, an adjusted or tangible figure after dividends. A standalone book value of INR 65.4/share (Screener latest) implies about INR 104 crore standalone. These differences reflect standalone vs consolidated bases and rating-agency adjustments. FY2026 consolidated equity is therefore shown as approximately INR 65–77 crore (consolidated/adjusted), with the standalone figure noted separately. (d) The jump in intangibles in FY2026 (INR 1.0 crore → INR 13.4 crore) is consistent with capitalised development and registration costs (dossiers, DMFs) or merger-related reclassification. The company has not explained it in the sources reviewed.
Treat it as indicative.
Cash flow
Source: stockanalysis.com consolidated cash flow; capex = operating cash flow – free cash flow (consistent with Stockopedia capex of INR 8.47/14.6/11.0 crore for FY2022–FY2024). Discrepancy: TipRanks shows operating cash flow of only INR 8.8 crore and INR 4.2 crore for its latest periods, possibly on a different (standalone or TTM) basis. Dividends paid are estimated at INR 1.20 × about 1.59 crore shares. No buybacks have been authorised.
Commentary. Cash generation is weak relative to reported EBITDA. Over five years, cumulative operating cash flow of about INR 99 crore was roughly matched by cumulative capex (about INR 72 crore) plus cash interest (about INR 74 crore). This explains why net debt rose by about INR 50 crore despite positive EBITDA. FY2023 was the stress year: a working-capital build of about INR 28 crore (inventory +INR 24 crore, receivables +INR 15 crore) pushed operating cash flow negative and required INR 24 crore of net financing. FY2026 improved, with operating cash flow up 49.9% to INR 30.4 crore. However, inventory rose to INR 116.4 crore (the highest in the series), so the working-capital gain came mostly from payables and other liabilities.
Ratios
ROA and ROIC are not cleanly computable from the verified data. An indicative estimate is ROA of about 1.7% for FY2026 (net income INR 6.3 crore over estimated total assets of about INR 370 crore) and ROIC of about 7–8% (post-tax EBIT over equity plus net debt of about INR 215–225 crore). Both are derived and should be treated as approximate. Asset turnover is about 0.85x in FY2026 (derived). Screener reports a 3-year average ROE of 7.62% (standalone view) and 8.51% (consolidated view).
Commentary. Leverage and liquidity are the critical issue. Net debt/EBITDA has stayed in the 3.7–4.8x band for five years. EBIT interest cover has deteriorated to about 1.2x, which leaves very little cushion against a margin shock. The cash conversion cycle has lengthened from 105 days (FY2022) to 176 days (FY2026). That is long even by Indian API standards and is driven by inventory build. Acuité reports average fund-based bank-limit utilisation of about 88% (and non-fund-based utilisation of about 76%) over the twelve months to June 2026, confirming tight working-capital headroom. The INR 8.4 crore promoter warrant issue (25% payable upfront under SEBI ICDR norms, with the balance on conversion) is a modest equity infusion relative to about INR 150 crore of net debt.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (INR Cr) | 281.2 | 304.2 | 339.2 | 303.1 | 311.7 |
Revenue growth YoY (%) | 12.25 | 8.18 | 11.51 | -10.65 | 2.83 |
Cost of revenue (INR Cr) | 172.2 | 178.2 | 197.4 | 163.2 | 158.0 |
Gross profit (INR Cr) | 109.1 | 126.0 | 141.8 | 139.9 | 153.7 |
SG&A (INR Cr) | 47.8 | 56.1 | 61.5 | 63.4 | 66.5 |
Operating income EBIT (INR Cr) | 14.9 | 17.4 | 21.6 | 20.0 | 20.8 |
EBITDA / operating profit (INR Cr, Screener) | 23 | 26 | 33 | 30 | 32 |
Interest expense (INR Cr) | 8.9 | 10.5 | 12.9 | 14.5 | 16.8 |
Pre-tax income (INR Cr) | 9.2 | 4.7 | 9.0 | 5.1 | 5.9 |
Income tax (INR Cr) | 3.5 | 2.1 | 1.6 | -2.1 | -0.4 |
Net income (INR Cr) | 5.7 | 2.6 | 7.4 | 7.2 | 6.3 |
EPS basic (INR; FY2022–24 derived) | 3.85 | 1.67 | 4.69 | 4.53 | 3.95 |
Dividend per share (INR) | — | — | — | 1.20 | 1.20 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 38.8 | 41.4 | 41.8 | 46.2 | 49.3 |
EBITDA margin (%) | 8.2 | 8.5 | 9.7 | 9.9 | 10.3 |
Operating (EBIT) margin (%) | 5.31 | 5.73 | 6.38 | 6.61 | 6.68 |
Pre-tax margin (%) | 3.3 | 1.5 | 2.7 | 1.7 | 1.9 |
Net margin (%) | 2.0 | 0.9 | 2.2 | 2.4 | 2.0 |
Income Statement and Per-Share Data
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 65.87 | 74.02 | 87.6 | 84.08 | 88.62 |
Net profit (INR Cr) | 0.21 | 0.72 | 1.79 | 3.60 | 1.13 |
EPS (INR) | 0.10 | — | 1.12 | 2.26 | — |
Liquidity & Coverage Ratios
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (INR Cr) | 1.1 | 1.5 | 4.2 | 1.8 | 7.2 |
Cash plus short-term investments (INR Cr) | 5.8 | 7.5 | 19.9 | 10.4 | 9.3 |
Receivables (INR Cr) | 82.9 | 97.7 | 104.3 | 96.7 | 94.8 |
Inventory (INR Cr) | 74.4 | 98.0 | 87.8 | 103.0 | 116.4 |
Total current assets (INR Cr) | 184.6 | 228.2 | 234.2 | 234.9 | 262.2 |
Property plant and equipment (INR Cr) | 57.2 | 62.2 | 64.8 | 73.8 | 84.2 |
Goodwill (INR Cr) | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 |
Other intangibles (INR Cr) | 0.2 | 1.3 | 1.2 | 1.0 | 13.4 |
Working capital (INR Cr) | 18.9 | 18.8 | 31.1 | 15.4 | 13.0 |
Net debt (INR Cr) | 100.8 | 125.6 | 122.3 | 141.9 | 150.2 |
Total debt derived (INR Cr) | 106.6 | 133.1 | 142.2 | 152.3 | 159.5 |
Balance Sheet
| Metric | FY2025 | FY2026 |
|---|---|---|
Total equity consolidated approx (INR Cr) | 77 | 77 |
Adjusted net worth per Acuite (INR Cr) | — | 65 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 26.8 | -1.5 | 22.8 | 20.3 | 30.4 |
Capex derived (INR Cr) | 8.5 | 14.7 | 11.0 | 18.8 | 18.6 |
Free cash flow (INR Cr) | 18.3 | -16.2 | 11.8 | 1.5 | 11.9 |
Investing cash flow (INR Cr) | -9.5 | -22.2 | -18.9 | -14.9 | -20.7 |
Financing cash flow (INR Cr) | -17.2 | 24.1 | -1.2 | -7.8 | -9.6 |
Cash interest paid (INR Cr) | 10.4 | 13.7 | 16.3 | 16.9 | 16.8 |
Dividends paid approx (INR Cr) | — | — | — | 1.9 | 1.9 |
Buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%; Screener latest = FY2026 TTM) | — | — | — | 9.84 | 6.65 |
ROCE (%; Screener) | — | — | — | 10.1 | 9.24 |
Current ratio (x; TipRanks) | 1.11 | 1.09 | 1.15 | 1.15 | — |
Debt to equity (x; TipRanks) | 1.82 | 2.05 | 2.05 | 2.05 | — |
Net debt to EBITDA (x; derived) | 4.4 | 4.8 | 3.7 | 4.7 | 4.7 |
Interest coverage EBIT to interest (x; derived) | 1.68 | 1.66 | 1.68 | 1.38 | 1.24 |
Interest coverage EBITDA to interest (x; derived) | 2.6 | 2.5 | 2.6 | 2.1 | 1.9 |
Cash conversion cycle (days; Screener) | 105 | 129 | 129 | 163 | 176 |
Free cash flow margin (%) | 6.52 | -5.32 | 3.49 | 0.50 | 3.81 |
Revenue by Region (%)
| Metric | H1FY21 | H1FY22 | Q1FY22 | Q1FY23 |
|---|---|---|---|---|
Export share of revenue (%) | 75 | 70 | 58 | 71 |
Domestic share of revenue (%) | 25 | 30 | 42 | 29 |
Valuation Snapshot
| Metric | Value | Date / source |
|---|---|---|
Latest observed price | INR 101–107 | Screener latest snapshot; IIFL 25 Sept 2026 (INR 107.43) |
Market capitalisation | INR 161–171 crore | Same |
52-week range | INR 60.0 – 124.6 | IIFL, 25 Sept 2026 |
1-year return | +23.2% | IIFL, 25 Sept 2026 |
3-year CAGR | +3.2% | IIFL, 25 Sept 2026 |
5-year CAGR | +0.1% | IIFL, 25 Sept 2026 |
6-month return | +57.8% | IIFL, 25 Sept 2026 |
All-time / multi-year high | INR 157.98 | Equentis (5-year high, as of Jan 2025) |
Metric | Mar2026 | Jun2026 |
Share price (INR) | 64 | 83.3 |
Market cap (INR Cr) | 102 | 139 |
Valuation Multiples
| Multiple | Bal Pharma | Peer reference | Source |
|---|---|---|---|
P/E (TTM) | 16.6–22.0x | Peer median about 26.6x | IIFL (Sept 2026: 21.96x); Value Research peer median |
P/B | 1.60–1.64x | Peer median about 4.49x | IIFL (Sept 2026) |
EV/EBITDA | About 9.2x (Tijori); about 9.9x derived at INR 165 crore market cap plus INR 150 crore net debt over INR 32 crore EBITDA | 3-year average 10.6x | Tijori; derived |
EV/Sales | About 1.0x (derived) | — | Derived |
Dividend yield | About 1.1–1.2% | — | Screener |
Credit Ratings
| Agency | Rating | Outlook | Date | Facilities |
|---|---|---|---|---|
Acuité | BBB- (LT) / A3 (ST) | Stable | Aug 2026 (reaffirmed) | Bank facilities (INR 162.5 crore LT plus INR 26.5 crore ST per 2025 rationale; 2026 amounts revised) |
Acuité | BBB- / A3 | Stable | 9 Jun 2025 | INR 162.5 crore LT; INR 26.5 crore ST |
ICRA | BB+ (Positive) / A4+ | Withdrawn | 2022 | At company request |
Analyst Conclusions
Guidance and consensus
Management provides no numeric guidance and no sell-side consensus exists. The best available "guidance" is qualitative: continued focus on API exports and domestic formulations, ramp-up of new API capacity from mid-2026, and entry into the Philippines through the JV.
Bull case
-
Revenue inflection plus operating leverage. Q1 FY2027 revenue of INR 88.6 crore (+34.5% YoY) is close to the FY2024 run-rate peak. If the new API capacity sustains an INR 90 crore-plus quarterly run-rate (about INR 360 crore annualised) and FY2026 gross margins of about 49% hold, EBITDA could rise above INR 40 crore. That would cut net debt/EBITDA below 4x without any debt reduction.
-
Structural margin uplift. Gross margin expanded 10.5 percentage points over four years. If interest stabilises, each incremental point of EBIT margin is worth about INR 3 crore, which is about 50% of FY2026 PAT.
-
Cheap optionality. At about 1.6x P/B and about 9–10x EV/EBITDA, against peer medians of about 4.5x P/B, the stock prices in little value for the Philippines JV, EU regulated-market FDF entry or future off-patent domestic launches. The promoter buying warrants at INR 84 also signals confidence.
Bear case
-
Balance-sheet fragility. EBIT/interest of about 1.2x, 88% utilisation of bank limits and a 176-day cash conversion cycle mean any margin or volume shock could push PBT towards zero. Q1 FY2026 already showed PBT of only INR 0.2 crore.
-
Concentration and therapy risk. Revenue historically depended on Gliclazide for about 45%. Competition, customer de-stocking or migration to newer anti-diabetic classes could hit the core cash generator, as the FY2025 revenue decline suggests.
-
Poor capital efficiency. ROE of about 6.7% and ROCE of about 9.2%, with a 5-year revenue CAGR of about 4.5% and a 5-year share-price CAGR of about 0.1%, show a long record of capex and working-capital investment that has not created per-share value. Tax-credit-assisted PAT flatters recent earnings.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Q2 FY2027 results | By mid-Nov 2026 | Can revenue stay above INR 85 crore while PBT expands? Interest trend |
| H1 FY2027 balance sheet | Nov 2026 | Inventory, receivables, net debt vs INR 150 crore |
| New API plant ramp-up | FY2027 | Utilisation, product approvals, PLI receipts |
| Philippines JV incorporation | FY2027 | Equity outlay, first registrations |
| Warrant conversion | Within 18 months of allotment | Remaining ~75% of the INR 8.4 crore |
| Lifezen merger decision | FY2027 | Simplification |
| Next Acuité review | ~Mid-2027 | Rating direction |
| New CS appointment / board changes | Ongoing | Governance continuity |
| Q3–Q4 FY2027 results | Feb / May 2027 | Full-year FY2027 PAT vs FY2026 |
Analyst verdict
Bal Pharma is a durable but under-earning niche API and formulations business. On the evidence of FY2022–FY2026, it has proved it can survive, but not that it can compound value. Its strengths are real. The company holds roughly a quarter of the global Gliclazide API market and supplies tier-one generic companies. It owns an integrated chain of six plants from intermediates to finished doses, and its gross margin has risen steadily to about 49%. Yet almost none of that improvement reached shareholders. Interest costs nearly doubled, working capital absorbed cash, and capex consumed most of operating cash flow. Net debt grew from about INR 101 crore to about INR 150 crore while net profit stayed around INR 6–7 crore. ROE in the high single digits, below the cost of equity, explains the flat five-year share-price CAGR.
The 2026 setup is the most constructive in several years. Revenue re-accelerated sharply in Q1 FY2027 to an annualised run-rate of about INR 355 crore. New API capacity began production in mid-2026. The promoter injected fresh equity at INR 84, and the Philippines JV opens a new distribution channel. A 58% six-month rally has already priced in part of this recovery. The stock now trades at about 22x trailing earnings, which is no longer a deep value multiple, although it still trades at a discount to peers on P/B and EV/EBITDA.
The investment case therefore depends on converting revenue growth into cash. The key tests are whether quarterly PBT can sustainably exceed INR 3–4 crore, whether the cash conversion cycle can be pulled back below about 150 days, and whether net debt/EBITDA can fall below 3.5x. Until two consecutive quarters confirm that, the balance of evidence supports a neutral, high-risk stance. The upside is operating leverage on a recovering topline; the downside is a thin interest cushion against a concentrated, competitive API franchise. Investors should size positions with the illiquidity of the stock and the absence of analyst coverage in mind.
Source list (principal)
-
Bal Pharma website: http://www.balpharma.com (profile, units, history timeline)
-
BSE/NSE filings: Board meeting outcomes (11 Feb 2026, 27 May 2026, 12 Aug 2026); Annual Reports FY2011-12 and FY2020-21; investor presentation (2021–22); press releases (Nov 2021, Aug 2022); related-party disclosures (2021)
-
ICRA rating rationales (Mar 2021, Sept 2021, Dec 2021; withdrawal 2022)
-
Acuité rating rationales (May 2024, Dec 2024, Jun 2025, Aug 2026)
-
stockanalysis.com (income statement, balance sheet, cash flow FY2022–FY2026)
-
screener.in (standalone and consolidated; ratios, announcements)
-
fyers.in, Kotak Neo, Univest (quarterly and annual results)
-
Upstox, Bajaj Finserv, Emkay/Dion Global (shareholding)
-
IIFL, ICICIdirect, Value Research, 5paisa, Choice India, Anand Rathi (prices, multiples)
-
CB Insights (Q1 FY2027 / Philippines JV summary); Similarweb signals; PharmaBoardroom (MD interview); company-background pages (Aditya Birla Money, MarketsMojo)
-
MCA-linked registries: thecompanycheck.com, infyner.com
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / notes | Background |
|---|---|---|---|
Shailesh D. Siroya (DIN 00048109) | Managing Director; promoter | MD since 1 Aug 2004; not liable to retire by rotation | Co-founder from the Micro Labs/Siroya family; led the company's niche-API strategy. |
Himesh Virupakshaya | Executive Director | On board since at least FY2021 | Operations / technical (details not disclosed) |
Nicola Neeladri | Independent Director | Since at least FY2021 | — |
Jatish Sheth | Non-Executive Director | Additional director from 28 Dec 2020; later regularised | — |
Ravindrakumar Kothari | Director | Listed among current directors (MCA data, 2026) | — |
Daddanala Venkat Bharath Bhushan | Director | Listed among current directors (MCA data) | — |
Bheekamchand Mukesh | Director | Listed among current directors (MCA data) | — |
G. Rengarajan | Chief Financial Officer | Signed filings as CFO in 2021 | — |
Archana Dubey | COO / EVP (per aggregator) | — | — |
Abdul Basith | Company Secretary & Compliance Officer (former) | Resigned by letter dated 2 March 2026; accepted 11 May 2026 | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Shares | Stake (%) | Category |
|---|---|---|---|
Shailesh Siroya | 2,745,459 | 17.24 | Promoter |
Micro Labs Limited | 2,011,736 | 12.64 | Promoter group |
Anita Siroya | 1,049,220 | 6.59 | Promoter group |
Prakash Chandra Jain | 581,270 | 3.65 | Public |
Ram Keshav Murthy | 527,600 | 3.31 | Public |
Anand Surana | 525,686 | 3.30 | Promoter group |
Chandraprakash Dheerajmal Siroya | 486,420 | 3.06 | Promoter group |
Dilip Surana | 474,994 | 2.98 | Promoter group (Emkay cites 6.45 lakh / 4.05% as of Dec 2025, a discrepancy) |
Naresh D.P. | 300,207 | 1.89 | Public |
Shreya Mardia | 300,000 | 1.88 | Public |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs Bal Pharma |
|---|---|---|
Niche/specialty API (small-cap India) | Smruthi Organics | Small-cap API peer (named in Tijori peer set) |
Niche/specialty API | Tyche Industries | Small API/intermediates peer (Tijori peer set) |
Niche API / formulations | Nano Pharmaceuticals; TJI Pharma | Micro-cap peers (Tijori peer set) |
API (mid-size) | SMS Pharmaceuticals | Larger API player, comparable niche-molecule strategy |
API (large) | Aarti Drugs | Larger, commodity-plus-specialty API maker |
Diabetes formulations (India) | Micro Labs (group company), USV, Glenmark, Sun Pharma, Mankind Pharma | Much larger branded franchises in anti-diabetics; Sun Pharma is also an API customer |
Export formulations (semi-regulated) | Balaxi Pharmaceuticals, Lincoln Pharmaceuticals, Medicamen Biotech | Comparable small-cap export formulators |
Micro-cap formulations | Vaishali Pharma | Named in TipRanks peer set |
IV fluids (India) | Baxter India, B. Braun, Fresenius Kabi, Albert David | Larger, scale-driven LVP producers |
Global Gliclazide API | Other Indian and Chinese API makers (not specifically identified) | Bal Pharma claims about 25% global share (ICRA 2021) |
Peer Comparison FY2026
| Metric | Bal Pharma | Balaxi Pharmaceuticals |
|---|---|---|
Q1 FY2027 revenue (INR Cr) | 88.6 | 80.7 |
Q1 FY2027 net profit (INR Cr) | 1.13 | 1.30 |
FY2026 revenue growth (%) | 2.8 | — |
FY2026 EBITDA margin (%) | 10.3 | — |
Recent Developments
Q2 FY2027 (September 2026 quarter) results had not been reported as of compilation. Under SEBI timelines they are due by mid-November 2026.*



